Emicizumab, a recombinant humanized bispecific monoclonal antibody, is used to replace the function of activated FVIII by binding to both activated factor IX and factor X. It is currently widely used for the prevention of bleeding in patients with congenital hemophilia A with or without inhibitors. This evidence concerns the gene F8 and hemophilia A.